Cargando…
Preliminary pharmaceutical development of antimalarial–antibiotic cotherapy as a pre-referral paediatric treatment of fever in malaria endemic areas
Artemether (AM) plus azithromycin (AZ) rectal co-formulations were studied to provide pre-referral treatment for children with severe febrile illnesses in malaria-endemic areas. The target profile required that such product should be cheap, easy to administer by non-medically qualified persons, rapi...
Autores principales: | Gaubert, Alexandra, Kauss, Tina, Marchivie, Mathieu, Ba, Boubakar B., Lembege, Martine, Fawaz, Fawaz, Boiron, Jean-Michel, Lafarge, Xavier, Lindegardh, Niklas, Fabre, Jean-Louis, White, Nicholas J., Olliaro, Piero L., Millet, Pascal, Gaudin, Karen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier/North-Holland Biomedical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4045394/ https://www.ncbi.nlm.nih.gov/pubmed/24726300 http://dx.doi.org/10.1016/j.ijpharm.2014.04.023 |
Ejemplares similares
-
Pharmaceutical development and optimization of azithromycin suppository for paediatric use
por: Kauss, Tina, et al.
Publicado: (2013) -
Screening paediatric rectal forms of azithromycin as an alternative to oral or injectable treatment
por: Kauss, Tina, et al.
Publicado: (2012) -
The initial pharmaceutical development of an artesunate/amodiaquine oral formulation for the treatment of malaria: a public-private partnership
por: Lacaze, Catherine, et al.
Publicado: (2011) -
Correction: Nguyen et al. Oligonucleotide Solid Nucleolipid Nanoparticles against Antibiotic Resistance of ESBL-Producing Bacteria. Pharmaceutics 2022, 14, 299
por: Nguyen, Phuoc Vinh, et al.
Publicado: (2022) -
Oligonucleotide Solid Nucleolipid Nanoparticles against Antibiotic Resistance of ESBL-Producing Bacteria
por: Nguyen, Phuoc Vinh, et al.
Publicado: (2022)